Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Regal Investment Advisors LLC

Regal Investment Advisors LLC increased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 39.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 35,976 shares of the biopharmaceutical company’s stock after purchasing an additional 10,217 shares during the period. Regal Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $1,494,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BMY. Gryphon Financial Partners LLC increased its position in Bristol-Myers Squibb by 23.5% during the fourth quarter. Gryphon Financial Partners LLC now owns 5,235 shares of the biopharmaceutical company’s stock worth $280,000 after purchasing an additional 995 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Bristol-Myers Squibb by 12.0% during the fourth quarter. The Manufacturers Life Insurance Company now owns 1,688,132 shares of the biopharmaceutical company’s stock valued at $86,618,000 after acquiring an additional 180,842 shares during the last quarter. CWA Asset Management Group LLC increased its position in shares of Bristol-Myers Squibb by 213.8% during the fourth quarter. CWA Asset Management Group LLC now owns 25,439 shares of the biopharmaceutical company’s stock valued at $1,305,000 after acquiring an additional 17,332 shares during the last quarter. NEOS Investment Management LLC increased its position in shares of Bristol-Myers Squibb by 72.7% during the fourth quarter. NEOS Investment Management LLC now owns 43,879 shares of the biopharmaceutical company’s stock valued at $2,251,000 after acquiring an additional 18,467 shares during the last quarter. Finally, Hudson Edge Investment Partners Inc. increased its position in shares of Bristol-Myers Squibb by 16.0% during the fourth quarter. Hudson Edge Investment Partners Inc. now owns 115,796 shares of the biopharmaceutical company’s stock valued at $5,941,000 after acquiring an additional 15,983 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on BMY shares. BMO Capital Markets reiterated a “market perform” rating and set a $48.00 price target on shares of Bristol-Myers Squibb in a research report on Monday, September 23rd. Cantor Fitzgerald restated a “neutral” rating and issued a $50.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, September 16th. TD Cowen lifted their price objective on shares of Bristol-Myers Squibb from $45.00 to $53.00 and gave the company a “hold” rating in a report on Monday, August 12th. Barclays lifted their price objective on shares of Bristol-Myers Squibb from $41.00 to $42.00 and gave the company an “underweight” rating in a report on Thursday, August 22nd. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a report on Tuesday, July 23rd. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $55.00.

Bristol-Myers Squibb Stock Up 1.6 %

Shares of NYSE:BMY opened at $51.74 on Tuesday. The company has a market capitalization of $104.88 billion, a PE ratio of -16.69, a P/E/G ratio of 12.96 and a beta of 0.46. The company has a current ratio of 1.16, a quick ratio of 1.02 and a debt-to-equity ratio of 2.86. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $58.06. The firm has a 50 day simple moving average of $48.71 and a 200-day simple moving average of $46.28.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.43. The business had revenue of $12.20 billion during the quarter, compared to the consensus estimate of $11.54 billion. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The company’s revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.75 EPS. On average, equities analysts predict that Bristol-Myers Squibb will post 0.77 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be issued a $0.60 dividend. The ex-dividend date is Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.64%. Bristol-Myers Squibb’s payout ratio is -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.